Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11932635 CRBN ligands and uses thereof

Patent 11932635 was granted and assigned to Kymera Therapeutics on March, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Kymera Therapeutics

0

Current Assignee

Kymera Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Nello Mainolfi0

Arthur F. Kluge0

Nan Ji0

Date of Patent

March 19, 2024

0

Patent Application Number

180592320

Date Filed

November 28, 2022

0

Patent Citations

US Patent 7208157 Proteolysis targeting chimeric pharmaceutical

0

US Patent 6949537 PI-3 kinase inhibitor prodrugs

0

US Patent 7041298 Proteolysis targeting chimeric pharmaceutical

0

US Patent 7071189 Heterocyclic compound and antitumor agent containing the same as active ingredient

0

US Patent 7074620 Controlling protein levels in eucaryotic organisms

0

US Patent 7173015 Inhibition of Syk kinase expression

0

US Patent 9750816 Methods to induce targeted protein degradation through bifunctional molecules

0

US Patent 9770512 Methods to induce targeted protein degradation through bifunctional molecules

0

...

Patent Primary Examiner

0

CPC Code

0

0

Patent abstract

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11932635 CRBN ligands and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.